AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14513923 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (non-abstinent)
Number of subjects: 0
Study 14513923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 0
Study 14513923 — intervention group
Group type: EXPERIMENTAL
Intervention: Never-smokers
Number of subjects: 0
Study 14513923 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 0
Study 14513923 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked exposure condition
Number of subjects: 0
Study 14513923 — intervention group
Group type: COMPARATOR
Intervention: Ex-smokers and never-smokers
Number of subjects: 0
Study 10548192 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines (Phase II)
Number of subjects: 321
Study 8752611 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral contraceptive therapy (30 micrograms ethinyl E2 plus 150 micrograms desogestrel)
Number of subjects: 14
Study 8752611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic oral contraceptive therapy
Number of subjects: 14
Study 8752611 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a, leuprolide acetate depot 3.75 mg)
Number of subjects: 14
Study 8752611 — intervention group
Group type: COMPARATOR
Intervention: Continuous oral contraceptive therapy
Number of subjects: 14
Study 8752611 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a)
Number of subjects: 14
Study 1790313 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried sodium phenytoin-milk formulation
Number of subjects: 0
Study 1790313 — intervention group
Group type: COMPARATOR
Intervention: Capsule formulation administered with water or milk
Number of subjects: 0
Study 6846435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm of calcium per day
Number of subjects: 36
Study 6846435 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 gm of calcium per day
Number of subjects: 36
Study 6846435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31828170 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaolin-impregnated gauze
Number of subjects: 26
Study 31828170 — intervention group
Group type: COMPARATOR
Intervention: Standard sterilized dry gauze (control group)
Number of subjects: 26
Study 29560937 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal doses of mexidol (750 mg infusion in 250 ml of 0.9% NaCl solution for 6 days)
Number of subjects: 60
Study 29560937 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 60
Study 26764419 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 23
Study 24630753 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (n=3319)
Number of subjects: 6632
Study 24630753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=3313)
Number of subjects: 6632
Study 22469232 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii‐IVR (interactive virtual reality Wii)
Number of subjects: 30
Study 22469232 — intervention group
Group type: COMPARATOR
Intervention: Conventional GDH rehabilitation (control group)
Number of subjects: 30
Study 19706214 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 74
Study 19706214 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 74
Study 19706214 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet
Number of subjects: 74
Study 19706214 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean + Low-carbohydrate (combined)
Number of subjects: 74
Study 19706214 — intervention group
Group type: COMPARATOR
Intervention: Support sessions participation
Number of subjects: 74
Study 19706214 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate group
Number of subjects: 74
Study 17242083 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 67
Study 17242083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 67
Study 17242083 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 67
Study 17242083 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 67
Study 15260182 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback with real-time spectrum analysis
Number of subjects: 12
Study 15260182 — intervention group
Group type: COMPARATOR
Intervention: Traditional voice training
Number of subjects: 12
Study 11576093 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study 11576093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg x kg(‐1)
Number of subjects: 90
Study 11576093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9818732 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisconsin Card Sorting Test (WCST)
Number of subjects: 13
Study 9818732 — intervention group
Group type: COMPARATOR
Intervention: Resting SPECT
Number of subjects: 13
Study 9818732 — intervention group
Group type: EXPERIMENTAL
Intervention: Order effect
Number of subjects: 13
Study 7711149 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition guideline involving a commercialized enteral diet administered in 6 sessions at three-hour intervals, starting with 100 cc per session up to a total of 400 cc (2400 kcal/day) with 100 cc of water added.
Number of subjects: 50
Study 2523656 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 to 20 mg twice daily
Number of subjects: 28
Study 2523656 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 to 100 mg once daily
Number of subjects: 28
Study 826948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nootropyl (Piracetam) 400 mg per day for 14 days
Number of subjects: 0
Study 826948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control in a double blind study)
Number of subjects: 0
Study 30206572 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass ionomer (Hv-GIC) restorations (Equia, GC)
Number of subjects: 134
Study 30206572 — intervention group
Group type: COMPARATOR
Intervention: Nanohybrid composite restorations (E&Ra/nanoC) with a three-step etch-and-rinse adhesive (Optibond FL, Kerr)
Number of subjects: 134
Study 26975498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy
Number of subjects: 527
Study 26975498 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 527
Study 24714403 — intervention group
Group type: COMPARATOR
Intervention: Electromagnetic targeting (Sureshot)
Number of subjects: 99
Study 24714403 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-hand technique using fluoroscopy
Number of subjects: 99
Study 23709457 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Hegu (LI4) for 20 min using TENS acupuncture pen
Number of subjects: 0
Study 23709457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 0
Study 20632888 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-microg whole-virion aluminum formulation
Number of subjects: 706
Study 20632888 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-microg split-virion nonaluminum formulation
Number of subjects: 706
Study 20632888 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-microg split-virion formulation
Number of subjects: 706
Study 20632888 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 706
Study 18257142 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 351
Study 18257142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 18257142 — intervention group
Group type: COMPARATOR
Intervention: Black cohosh and multibotanical herbs
Number of subjects: 351
Study 14687955 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous depot injection of 58 mg buprenorphine
Number of subjects: 5
Study 11949771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-depleted drink
Number of subjects: 14
Study 11949771 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (pharmacological challenge)
Number of subjects: 14
Study 11949771 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 14
Study 9541518 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-impact exercise three times a week for 18 months (n=35)
Number of subjects: 80
Study 9541518 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising controls (n=45)
Number of subjects: 80
Study 7534716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan (HDM) with autologous bone marrow rescue (ABMR)
Number of subjects: 29
Study 7534716 — intervention group
Group type: COMPARATOR
Intervention: High-dose melphalan (HDM) without autologous bone marrow rescue (ABMR)
Number of subjects: 29
Study 7534716 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) with autograft
Number of subjects: 29
Study 7534716 — intervention group
Group type: COMPARATOR
Intervention: High-dose melphalan (HDM)
Number of subjects: 29
Study 7534716 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-4 (rIL-4) in vitro
Number of subjects: 29
Study 7534716 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF)
Number of subjects: 29
Study 2502935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg)
Number of subjects: 10
Study 2502935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 961724 — intervention group
Group type: EXPERIMENTAL
Intervention: blocking plus instructions
Number of subjects: 24
Study 961724 — intervention group
Group type: EXPERIMENTAL
Intervention: blocking plus labels
Number of subjects: 24
Study 961724 — intervention group
Group type: COMPARATOR
Intervention: blocking
Number of subjects: 24
Study 31703653 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive lifestyle behaviours (exercise for weight reduction)
Number of subjects: 821
Study 31703653 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive lifestyle behaviours (lowered food intake)
Number of subjects: 821
Study 31703653 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive lifestyle behaviours (added vegetables to diet)
Number of subjects: 821
Study 31703653 — intervention group
Group type: EXPERIMENTAL
Intervention: High birth weight (BW ≥ 3500 g)
Number of subjects: 821
Study 31703653 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with both parents having OW/OB
Number of subjects: 821
Study 31703653 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with one parent having OW/OB
Number of subjects: 821
Study 31703653 — intervention group
Group type: COMPARATOR
Intervention: Children with normal-weight parents
Number of subjects: 821
Study 27068368 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based outpatient physiotherapy (six group-based exercise sessions after surgery)
Number of subjects: 46
Study 27068368 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard postoperative care)
Number of subjects: 46
Study 27068368 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based outpatient physiotherapy
Number of subjects: 46
Study 27068368 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 27068368 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment
Number of subjects: 46
Study 27068368 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal
Number of subjects: 46
Study 25961283 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01E or F4/AS01B followed by Ad35-GRIN
Number of subjects: 146
Study 25961283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN followed by two doses of F4/AS01B
Number of subjects: 146
Study 25961283 — intervention group
Group type: EXPERIMENTAL
Intervention: Three co-administrations of Ad35-GRIN and F4/AS01B
Number of subjects: 146
Study 25961283 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01
Number of subjects: 146
Study 25961283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN
Number of subjects: 146
Study 25961283 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of an adjuvanted protein and an adenovirus vector
Number of subjects: 146
Study 23370859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BR)
Number of subjects: 14
Study 23370859 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted placebo juice (PL)
Number of subjects: 14
Study 21596327 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 436
Study 21596327 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 436
Study 19022642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 microg via Respimat SMI
Number of subjects: 207
Study 19022642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 10 microg via Respimat SMI
Number of subjects: 207
Study 19022642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg via HandiHaler
Number of subjects: 207
Study 19022642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 16420273 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on the mucosa buccally, distally and palatally to the canine
Number of subjects: 12
Study 16420273 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (pseudo-application)
Number of subjects: 12
Study 15452472 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated saline
Number of subjects: 34
Study 15452472 — intervention group
Group type: COMPARATOR
Intervention: Oxypolygelatine (OXY)
Number of subjects: 34
Study 11469844 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of ampiroxicam
Number of subjects: 120
Study 11469844 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 9394367 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (Arimidex)
Number of subjects: 0
Study 9394367 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (general)
Number of subjects: 0
Study 7696598 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant tones presented to patients with Alzheimer's disease (AD)
Number of subjects: 19
Study 7696598 — intervention group
Group type: COMPARATOR
Intervention: Deviant tones presented to healthy older subjects (control group)
Number of subjects: 19
Study 3312372 — intervention group
Group type: COMPARATOR
Intervention: Monosodium L-glutamate (MSG) 500 mg capsules, increasing doses from 0.5 gm to 5.0 gm
Number of subjects: 32
Study 30107833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal washing
Number of subjects: 295
Study 30107833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal lubrication
Number of subjects: 295
Study 30107833 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in Tijuana
Number of subjects: 295
Study 30107833 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 295
Study 30107833 — intervention group
Group type: EXPERIMENTAL
Intervention: Being born in the same state as the study site
Number of subjects: 295
Study 30107833 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly income ≥3500 pesos
Number of subjects: 295
Study 30107833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous alcohol consumption
Number of subjects: 295
Study 27895844 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of live, oral rotavirus vaccine
Number of subjects: 4939
Study 27895844 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of live, oral rotavirus vaccine
Number of subjects: 4939
Study 27895844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4939
Study 27895844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled vaccine group (two or three doses of vaccine)
Number of subjects: 4939
Study 27895844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled vaccine group
Number of subjects: 4939
Study 24215217 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TENS)
Number of subjects: 65
Study 24215217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham stimulation)
Number of subjects: 65
Study 22372517 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 25 mg liquid capsules
Number of subjects: 132
Study 22372517 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac-K 12.5 mg tablets
Number of subjects: 132
Study 22372517 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 200 mg liquid capsules
Number of subjects: 132
Study 22372517 — intervention group
Group type: COMPARATOR
Intervention: ASA 500 mg tablets
Number of subjects: 132
Study 20541301 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg orally, 4 doses at 12-hour intervals
Number of subjects: 60
Study 20541301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20541301 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 60
Study 18164324 — intervention group
Group type: EXPERIMENTAL
Intervention: Team training intervention (multiphasic staff training program over 6 months)
Number of subjects: 487
Study 18164324 — intervention group
Group type: COMPARATOR
Intervention: Control group (site-specific team performance profiles with recommendations)
Number of subjects: 487
Study 15565899 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin treatment
Number of subjects: 0
Study 15565899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight perioperative glycemic control
Number of subjects: 0
Study 15565899 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (enteral formulas enriched with arginine, omega‐3 fatty acids, glutamine, and RNA)
Number of subjects: 0
Study 11281512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 26
Study 11281512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9395900 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic blood cell transplantation (alloBCT)
Number of subjects: 33
Study 9395900 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 33
Study 9395900 — intervention group
Group type: COMPARATOR
Intervention: Autologous blood cell transplantation (autoBCT)
Number of subjects: 33
Study 7892705 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 100
Study 7892705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (Fansidar)
Number of subjects: 100
Study 7892705 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 100
Study 3117488 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynovlar (3000 micrograms norethisterone and 50 micrograms ethinyl estradiol)
Number of subjects: 40
Study 3117488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovral (250 micrograms levonorgestrel and 50 micrograms ethinyl estradiol)
Number of subjects: 40
Study 3117488 — intervention group
Group type: EXPERIMENTAL
Intervention: Minipill (30 micrograms levonorgestrel only)
Number of subjects: 40
Study 3117488 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynovlar
Number of subjects: 40
Study 3117488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovral
Number of subjects: 40
Study 3117488 — intervention group
Group type: EXPERIMENTAL
Intervention: Minipill
Number of subjects: 40
Study 31161606 — intervention group
Group type: COMPARATOR
Intervention: Multicomponent educational intervention for parents and adolescents (P + A)
Number of subjects: 11
Study 31161606 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 31161606 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for parents only (P only)
Number of subjects: 11
Study 30591656 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Zinc (PZ) tablets (7 mg/day)
Number of subjects: 512
Study 30591656 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Zinc (TZ) supplements for diarrhea treatment (20 mg/day for 10 days)
Number of subjects: 512
Study 30591656 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Powder (MNP) sachets (10 mg zinc and 14 other micronutrients)
Number of subjects: 512
Study 30591656 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 512
Study 27574788 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 5 mg
Number of subjects: 640
Study 27574788 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 15 mg
Number of subjects: 640
Study 27574788 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 45 mg
Number of subjects: 640
Study 27574788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study 25201763 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent skin care (oil bath (0.5 dl) and facial fat cream)
Number of subjects: 56
Study 25201763 — intervention group
Group type: COMPARATOR
Intervention: Observation group (no intervention)
Number of subjects: 56
Study 22349085 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg caffeine
Number of subjects: 16
Study 22349085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19200991 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU of rLH daily for 4 days
Number of subjects: 0
Study 19200991 — intervention group
Group type: COMPARATOR
Intervention: 150 IU of rFSH for the first 5 days at suppression
Number of subjects: 0
Study 17341571 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric loads of 0, 300, 700 kcal infused by nasogastric tube
Number of subjects: 15
Study 15849701 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hookworm and schistosomiasis in the Intervention group
Number of subjects: 600
Study 15849701 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated children)
Number of subjects: 600
Study 11762611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg daily
Number of subjects: 8
Study 11762611 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge with Dapsone after withdrawal
Number of subjects: 8